The estimated Net Worth of Richard W Dugan is at least $603 Tysiąc dollars as of 31 May 2022. Mr. Dugan owns over 15,000 units of Vanda Pharmaceuticals Inc stock worth over $368,444 and over the last 20 years he sold VNDA stock worth over $0. In addition, he makes $234,988 as Independent Director at Vanda Pharmaceuticals Inc.
Sign up
Mr. Dugan VNDA stock SEC Form 4 insiders trading
Richard has made over 6 trades of the Vanda Pharmaceuticals Inc stock since 2015, according to the Form 4 filled with the SEC. Most recently he exercised 15,000 units of VNDA stock worth $62,250 on 31 May 2022.
The largest trade he's ever made was exercising 15,000 units of Vanda Pharmaceuticals Inc stock on 31 May 2022 worth over $62,250. On average, Richard trades about 3,056 units every 94 days since 2004. As of 31 May 2022 he still owns at least 74,887 units of Vanda Pharmaceuticals Inc stock.
You can see the complete history of Mr. Dugan stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Richard Dugan biography
Richard W. Dugan is an Independent Director of the Company. Mr. Dugan served as a Partner with Ernst & Young, LLP from 1976 to September 2002, where he served in a variety of managing and senior partner positions, including Mid-Atlantic Area Senior Partner from 2001 to 2002, Mid-Atlantic Area Managing Partner from 1989 to 2001 and Pittsburgh Office Managing Partner from 1979 to 1989. Mr. Dugan retired from Ernst & Young, LLP in September 2002. Mr. Dugan previously served as a director of two publicly traded pharmaceutical companies, Middlebrook Pharmaceuticals, Inc. and Critical Therapeutics, Inc., and a privately owned pharmaceutical company, Xanthus Pharmaceuticals. Mr. Dugan holds a B.S.B.A. from Pennsylvania State University.
What is the salary of Richard Dugan?
As the Independent Director of Vanda Pharmaceuticals Inc, the total compensation of Richard Dugan at Vanda Pharmaceuticals Inc is $234,988. There are 11 executives at Vanda Pharmaceuticals Inc getting paid more, with Mihael Polymeropoulos having the highest compensation of $4,278,140.
How old is Richard Dugan?
Richard Dugan is 78, he's been the Independent Director of Vanda Pharmaceuticals Inc since 2005. There are no older and 15 younger executives at Vanda Pharmaceuticals Inc.
What's Richard Dugan's mailing address?
Richard's mailing address filed with the SEC is 298 BEACON CIRCLE, , BOALSBURG, PA, 16827.
Insiders trading at Vanda Pharmaceuticals Inc
Over the last 19 years, insiders at Vanda Pharmaceuticals Inc have traded over $267,060,716 worth of Vanda Pharmaceuticals Inc stock and bought 5,567,934 units worth $25,606,507 . The most active insiders traders include Kevin Ctang Capital Managem..., Nicole Vitullo oraz Jesse I Treu. On average, Vanda Pharmaceuticals Inc executives and independent directors trade stock every 31 days with the average trade being worth of $546,607. The most recent stock trade was executed by Kevin Patrick Moran on 29 July 2024, trading 2,251 units of VNDA stock currently worth $13,326.
What does Vanda Pharmaceuticals Inc do?
vanda is a specialty pharmaceutical company focused on the development and commercialization of novel therapies to address high unmet medical needs and improve the lives of patients.
What does Vanda Pharmaceuticals Inc's logo look like?
Complete history of Mr. Dugan stock trades at Vanda Pharmaceuticals Inc i Cortexyme Inc
Vanda Pharmaceuticals Inc executives and stock owners
Vanda Pharmaceuticals Inc executives and other stock owners filed with the SEC include:
-
Mihael Polymeropoulos,
President, Chief Executive Officer, Director -
Timothy Williams,
Senior Vice President, General Counsel, Secretary -
Gunther Birznieks,
Senior Vice President - Business Development -
Dr. Mihael H. Polymeropoulos M.D.,
Founder, Pres, CEO & Chairman of The Board -
Dr. Mihael H. Polymeropoulos,
Founder, Pres, CEO & Director -
Joakim Wijkstrom,
Sr. VP & Chief Marketing Officer -
Kevin Patrick Moran,
Sr. VP, CFO & Treasurer -
Timothy Williams,
Sr. VP, Gen. Counsel & Sec. -
Phaedra Chrousos,
Independent Director -
Anne Ward,
Independent Director -
H. Thomas Watkins,
Independent Chairman of the Board -
Richard Dugan,
Independent Director -
Stephen Mitchell,
Independent Director -
Aranthan Jones,
Chief Corporate Affairs and Communications Officer -
Joakim Wijkstrom,
Senior Vice President, Chief Marketing Officer -
Kevin Moran,
Acting Chief Financial Officer, Vice President, Treasurer -
Elizabeth Van Every,
Head of Corp. Affairs -
Scott L. Howell,
Chief People Officer -
Kenneth Bate,
Director -
Michael F Cola,
Director -
James E Deerfield Mgmt L.P....,
-
Paolo Baroldi,
Chief Medical Officer -
Vincent Milano,
Director -
Steven A Shallcross,
Sr. VP, CFO, Treasurer -
Albert W. Gianchetti,
Sr.VP,Chief Commercial Officer -
Tage Honore,
-
Richard L. Gulino,
SVP & General Counsel -
James Patrick Kelly,
EVP & Chief Financial Officer -
Gian Piero Reverberi,
SVP & Chief Commercial Officer -
James B Tananbaum,
Director -
Capital Ii Llccare Capital ...,
-
Robert J More,
10% owner -
Nicole Vitullo,
10% owner -
Management Co Ii Llcprospec...,
-
Brian H Dovey,
10% owner -
Deepak Shripad Phadke,
Vice President Manufacturing -
Ventures Iv Lprho Ventures ...,
-
James C Blair,
10% owner -
Inc /De Medimmune,
10% owner -
Wayne T Hockmeyer,
Director -
Ventures Iv Lprho Managemen...,
-
Vi Associates, L.P. Dp,
10% owner -
Partners Vi, L.P. Domain,
10% owner -
Venture Partners Ii Lpprosp...,
-
Jesse I Treu,
10% owner -
Sciences Investment Fund Pt...,
-
Kathleen K Schoemaker,
10% owner -
Thomas Edward Gibbs,
SVP, Chief Commercial Officer -
James E Deerfield Mgmt L.P....,
-
Howard H Pien,
Director -
Steven K Galson,
Director -
Robert Repella,
SVP & Chief Commercial Officer -
Stephanie Rast Irish,
Sr. VP, Acting CFO/Treasurer -
John Joseph Feeney,
Acting Chief Medical Officer -
Argeris N Karabelas,
Chairman of the Board -
Brian K Halak,
Director -
William D Clark,
Sr VP, Chief Business Officer -
David Russ Ramsay,
Director -
Kevin Ctang Capital Managem...,